{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyponatraemia/management/management/","result":{"pageContext":{"chapter":{"id":"bf8b2972-5f8b-587a-935c-8f4a06208987","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field e6df20a7-a1fe-482e-8d13-a701015e2820 --><h2>Scenario: Management</h2><!-- end field e6df20a7-a1fe-482e-8d13-a701015e2820 -->","summary":"Covers the primary care management of people with hyponatraemia. It also briefly covers the initial management of hyponatraemia in secondary care.","htmlStringContent":"<!-- begin item cfe53729-d076-4a68-b8d5-a701015e2820 --><!-- begin field c98141ba-6880-4e18-a2a2-acbc01584857 --><p>From age 18 years onwards.</p><!-- end field c98141ba-6880-4e18-a2a2-acbc01584857 --><!-- end item cfe53729-d076-4a68-b8d5-a701015e2820 -->","topic":{"id":"0a0a0516-fca2-530d-88cd-096861572e3a","topicId":"560440de-b2ae-4ea7-9fb2-a701015e193f","topicName":"Hyponatraemia","slug":"hyponatraemia","lastRevised":"Last revised in November 2020","chapters":[{"id":"2d0342b8-1d8f-5b76-af1d-5c62137a465c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94ef9729-defa-5118-80c3-603843005f8a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0e655e55-4b6c-5ca3-9d0a-bcf5afa498d8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"262d0445-6fa5-53ed-8b8c-037da1983e4f","slug":"changes","fullItemName":"Changes"},{"id":"f79882a4-6b50-5264-a45b-2d43249a3418","slug":"update","fullItemName":"Update"}]},{"id":"8705184f-c02d-5cb2-9294-d85860c5d56e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"815d5ca9-eab9-5381-8a01-784808ab6cc7","slug":"goals","fullItemName":"Goals"},{"id":"85b3dae2-f267-5123-913e-442f138841bb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80e3ca36-d509-55eb-a763-7ccfa16bcafa","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5a45e73-9ef1-5cc7-9cee-cd7c7219e953","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9b557451-4a38-5431-a228-8e1d27043742","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3c76bef5-59b5-5e3e-b95c-72fd0f7370fb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2dda3afa-6384-564b-9938-f26680c7b906","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c2b54f92-5f73-5871-be34-52c87c49e81f","slug":"definition","fullItemName":"Definition"},{"id":"336f0b50-af95-5811-8819-05ebe4104ffb","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"2f18ae19-5934-5b36-8f56-cfbc5010c984","slug":"causes","fullItemName":"Causes"},{"id":"475e9aa0-653a-537b-988e-7f4bcf86f27a","slug":"incidence-prevelance","fullItemName":"Incidence and prevelance"},{"id":"f9af97ee-3a11-59b0-9533-e9a4ed3f8900","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8887725e-10a2-544c-8f35-8094785500e3","slug":"complications","fullItemName":"Complications"}]},{"id":"1fb71225-29dc-5a7a-a4e6-edf212ae9225","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6c1bda17-ccd5-52a4-9299-93f536f69e45","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"abaaf6cd-c698-507a-8fe7-feb15605c044","slug":"assessing-a-person-with-hyponatraemia","fullItemName":"Assessing a person with hyponatraemia"}]},{"id":"3f1780bb-24f2-5fae-a374-4de7113ad17f","fullItemName":"Management","slug":"management","subChapters":[{"id":"bf8b2972-5f8b-587a-935c-8f4a06208987","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"23dd936f-0ccd-5303-9c4d-504c43e5f8c8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5b75e52d-5896-50b9-9baf-e0fe2b5acf38","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6c996d4b-7572-5b4c-8adb-efc4b888b240","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a0a19e6f-1376-5caf-95d6-5492111dbefe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"73af9656-0aa1-53b8-b41a-855898c14f79","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f9132882-237e-5da1-86ef-fac89422fbc6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0c67dc74-d944-572d-9995-f93fb7844ef9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6781f94c-c836-5a66-b9df-5ef91879b82b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3f1780bb-24f2-5fae-a374-4de7113ad17f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"2f45971c-81b5-50bf-a549-97da27f527cc","slug":"admission-referral","fullItemName":"Admission/referral","depth":3,"htmlHeader":"<!-- begin field e175f219-d6d7-4394-88e8-a701015e2820 --><h3>When should I admit or refer a person with hyponatraemia?</h3><!-- end field e175f219-d6d7-4394-88e8-a701015e2820 -->","summary":null,"htmlStringContent":"<!-- begin item 9a0daab5-e662-4190-b038-a701015e2820 --><!-- begin field 671d9aab-6a1f-4786-ab03-a701015e2820 --><ul><li><strong>Admit the person to </strong><strong>hospital</strong><strong> immediately if they:</strong><ul><li>Have acute onset (duration for less than 48 hours) or severe (serum sodium concentration of less than 125 mmol/L) hyponatraemia.</li><li>Are <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/diagnosis/when-to-suspect/\">symptomatic</a>.</li><li>Have <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/diagnosis/assessing-a-person-with-hyponatraemia/\">signs of hypovolaemia</a>.</li></ul></li><li><strong>Discuss with an endocrinologist about the need for admission or referral:</strong><ul><li>If the person has asymptomatic, moderate hyponatraemia (serum sodium concentration of 125–129 mmol/L).</li></ul></li><li><strong>Arrange an urgent 2-week wait referral to the appropriate specialist:</strong><ul><li>If malignant disease is suspected as an underlying cause of <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">syndrome of inappropriate antidiuretic hormone secretion</a> (SIADH).</li></ul></li><li><strong>Refer to an endocrinologist, the urgency depending on clinical judgement:</strong><ul><li>If the cause of hyponatraemia is not clear.</li><li>If SIADH or another endocrine cause is suspected.<ul><li style=\"box-sizing: inherit;\">Hyponatraemia related to an <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">endocrine disorder</a> is uncommon, and will require specialist input to confirm the diagnosis and initiate treatment.</li><li style=\"box-sizing: inherit;\">If Addison's disease is suspected, admission or urgent referral may be required. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/addisons-disease/\">Addison's disease</a> for more information.</li></ul></li><li>If <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">reset osmostat syndrome</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">cerebral salt-wasting</a> is suspected.</li></ul></li><li><strong>Refer to an appropriate specialist:</strong><ul><li>If the person has hyponatraemia thought to be caused by heart failure, kidney disease, or liver disease. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a> and <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information.</li></ul></li></ul><!-- end field 671d9aab-6a1f-4786-ab03-a701015e2820 --><!-- end item 9a0daab5-e662-4190-b038-a701015e2820 -->","subChapters":[{"id":"39de0c17-4739-5261-8bf1-b7b8e16971e2","slug":"secondary-care-management","fullItemName":"Secondary care management","depth":4,"htmlHeader":"<!-- begin field 69e278cb-3790-4f11-9bea-ac73016c88ee --><h4>Secondary care management of</h4><!-- end field 69e278cb-3790-4f11-9bea-ac73016c88ee -->","summary":null,"htmlStringContent":"<!-- begin item 9e9aef3d-f36c-4f79-a901-7215a18e7fce --><!-- begin field 00179369-4b23-46bf-bdff-ac73016c88ee --><ul><li><strong>Secondary care management <strong>of hyponatraemia</strong> is aimed at determining and treating the underlying cause. Management strategies depend on the rate of onset of hyponatraemia, the person's symptoms, and their volume status.</strong><ul><li>Acute hyponatraemia with moderate or severe symptoms:<ul><li> Hypertonic saline restores serum sodium concentration to a safe level to correct any cerebral oedema and reduce the risk of complications.</li></ul></li><li>Acute hyponatraemia with mild or no symptoms:<ul><li>Non-essential parenteral fluids and medications that can provoke hyponatraemia are stopped and treatment is directed at the underlying cause.</li></ul></li><li>Chronic hyponatraemia without moderate or severe symptoms:<ul><li>Non-essential supplementary fluids and medications that can provoke hyponatraemia are stopped and treatment is directed at the underlying cause.</li></ul></li><li>People with hypervolaemia:<ul><li>Fluid restriction is recommended to prevent further fluid overload.</li></ul></li><li>People with hypovolaemia:<ul><li>Extracellular volume is restored with infusion of 0.9% saline.</li></ul></li><li>People with <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">syndrome of inappropriate antidiuretic hormone secretion</a> (SIADH):<ul><li>Fluid restriction is recommended. If there is no clear cause for SIADH following initial investigations, CT chest/abdomen/pelvis and MRI head may be arranged to exclude underlying malignancy.</li><li>Tolvaptan (a vasopressin V2-receptor antagonist) is indicated in adults for the treatment of hyponatremia secondary to SIADH. Treatment should be initiated in hospital or under specialist supervision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Joint Formulary Committee, 2020</a>].</li></ul></li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">GAIN, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Spasovski, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Saeed, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Dineen, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Woodward, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>]<span class=\"NormalTextRun SCXW160456896 BCX0\"> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Seay, 2020</a>]</span></p><!-- end field 00179369-4b23-46bf-bdff-ac73016c88ee --><!-- end item 9e9aef3d-f36c-4f79-a901-7215a18e7fce -->","subChapters":[]},{"id":"7c55fc9a-2b47-594c-a89f-d38083385e96","slug":"basis-for-recommendation-f58","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3dce972d-4a85-41f1-a44f-a701015e2820 --><h4>Basis for recommendation</h4><!-- end field 3dce972d-4a85-41f1-a44f-a701015e2820 -->","summary":null,"htmlStringContent":"<!-- begin item f58d9bd8-9246-4d41-937f-a701015e2820 --><!-- begin field e860857d-b4da-49c8-ae59-a701015e2820 --><p>This information is based on expert opinion in the <em>Clinical practice guideline on diagnosis and treatment of hyponatraemia</em> developed jointly by the European Society of Intensive Care Medicine (ESICM), the European Society of Endocrinology (ESE), and the European Renal Association-European Dialysis and Transplant Association (ERA–EDTA) represented by European Renal Association (ERA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Spasovski, 2014</a>], <em>Hyponatraemia in adults (on or after 16th birthday) </em>published by the Guideline and Audit Implementation Network (GAIN) for the Northern Ireland Department of Health [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">GAIN, 2010</a>], the US guideline <em>Diagnosis, evaluation, and treatment of hyponatraemia: expert panel recommendations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Verbalis, 2013</a>], <em>Investigation and management of hyponatraemia in adults in primary care </em>published by the York Teaching Hospital NHS Foundation Trust [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jones, 2019</a>], and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Reynolds, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Chubb, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Woodward, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jacob, 2019</a>].</p><h6>Hospital admission</h6><ul><li>Expert opinion in the Society for Endocrinology guideline is that people with severe symptoms require immediate treatment with hypertonic saline, irrespective of the cause of the hyponatraemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Ball, 2016</a>]. </li><li>Expert opinion in a review article is that acute symptomatic hyponatraemia is a medical emergency, and treatment should not be delayed pending a diagnosis of the cause of hyponatraemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Woodward, 2018</a>].</li></ul><h6>Referral</h6><ul><li>The recommendation to refer if the cause is not clear is based on what CKS considers to be good clinical practice.<ul><li>In most people, hyponatraemia is multifactorial, and interpretation of urinary sodium concentration and urinary osmolality can sometimes be difficult and unreliable [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Reynolds, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Chubb, 2009</a>]. Therefore, specialist referral is appropriate if hyponatraemia is persistent and no cause can be identified in primary care.</li></ul></li><li>The recommendation to arrange an urgent 2-week wait referral to the appropriate specialist if malignant disease is suspected as an underlying cause of syndrome of inappropriate antidiuresis is based on what CKS considers to be good clinical practice.</li><li>The recommendation to refer if SIADH or other endocrine disease is suspected is based on what CKS considers to be good clinical practice.</li><li>The recommendation on arranging an urgent 2-week wait referral is based on what CKS considers to be good clinical practice.</li></ul><!-- end field e860857d-b4da-49c8-ae59-a701015e2820 --><!-- end item f58d9bd8-9246-4d41-937f-a701015e2820 -->","subChapters":[]}]},{"id":"62b672be-3247-5781-8675-05c4d3c9f325","slug":"primary-care-management","fullItemName":"Primary care management","depth":3,"htmlHeader":"<!-- begin field 5bcbb199-152c-4edf-ad19-a76900baab8a --><h3>How should I manage a person with hyponatraemia in primary care?</h3><!-- end field 5bcbb199-152c-4edf-ad19-a76900baab8a -->","summary":null,"htmlStringContent":"<!-- begin item 630ab940-3f32-45ea-b8dd-a76900baaa37 --><!-- begin field 17f69012-c3ee-4fbb-b153-a76900baab8a --><ul><li><strong>People with asymptomatic, mild hyponatraemia</strong> (serum sodium concentration of 130–135 mmol/L) may be managed in primary care.<ul><li><strong>In all people,</strong> ensure a repeat serum sodium measurement has been taken to exclude a rapidly decreasing serum sodium concentration, which will require admission to hospital.</li><li><strong>If the person has an acute illness</strong> <strong>that may be contributing to the hyponatraemia, </strong>treat the underlying problem and recheck the serum sodium concentration after 2 weeks or sooner based on clinical judgement.</li><li><strong>If the person is taking a <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/#additional-information-on-causes\">medication</a></strong> <strong>that may be contributing to the hyponatraemia,</strong> stop this if appropriate and recheck the serum sodium concentration after 2 weeks.<ul><li>If the person is taking a medication that cannot be stopped (for example an antipsychotic), contact their appropriate specialist to discuss whether to stop the medication, monitor the serum sodium concentration, or refer to an endocrinologist or nephrologist.</li><li>If the serum sodium concentration remains low after stopping the medication, assess for another underlying <a class=\"topic-reference internal-reference\" href=\"/topics/hyponatraemia/background-information/causes/\">cause</a> or refer the person to an endocrinologist.</li></ul></li><li><strong>Provide patient information on hyponatraemia.</strong><ul><li>The National Kidney Foundation website (<a href=\"https://www.kidney.org/\" data-hyperlink-id=\"ca402a13-94f0-4700-8d8a-ac7b00097a30\">www.kidney.org</a>) has patient information on <a href=\"https://www.kidney.org/atoz/content/hyponatremia\" data-hyperlink-id=\"04883582-86ae-48e2-b419-ac7b00097bb9\">Hyponatraemia</a>.</li></ul></li></ul></li></ul><!-- end field 17f69012-c3ee-4fbb-b153-a76900baab8a --><!-- end item 630ab940-3f32-45ea-b8dd-a76900baaa37 -->","subChapters":[{"id":"ce3de1aa-e8f1-5fff-8f9e-a6d0df56f1df","slug":"basis-for-recommendation-4b9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5d886a92-7c8f-4c23-a969-a76900baab8f --><h4>Basis for recommendation</h4><!-- end field 5d886a92-7c8f-4c23-a969-a76900baab8f -->","summary":null,"htmlStringContent":"<!-- begin item 4b97fd5a-7436-4274-9bf5-a76900baab8f --><!-- begin field 0197060d-0c97-4d35-a128-a76900baab8f --><p>This information is based on expert opinion in the <em>Clinical practice guideline on diagnosis and treatment of hyponatraemia</em> developed jointly by the European Society of Intensive Care Medicine (ESICM), the European Society of Endocrinology (ESE), and the European Renal Association-European Dialysis and Transplant Association (ERA–EDTA) represented by European Renal Association (ERA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Spasovski, 2014</a>], <em>Hyponatraemia in adults (on or after 16th birthday) </em>published by the Guideline and Audit Implementation Network (GAIN) for the Northern Ireland Department of Health [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">GAIN, 2010</a>], the US guideline <em>Diagnosis, evaluation, and treatment of hyponatraemia: expert panel recommendations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Verbalis, 2013</a>], <em>Investigation and management of hyponatraemia in adults in primary care </em>published by the York Teaching Hospital NHS Foundation Trust [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jones, 2019</a>], and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Woodward, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jacob, 2019</a>].</p><h6>Primary care management</h6><ul><li>Expert opinion in the York Hospital guideline is that if the person is well, which may be the case with quite low serum sodium levels (especially if this has fallen slowly), then it may be reasonable to investigate for the underlying cause through primary care. Whether or not the person needs to be admitted to hospital or referral to secondary care may then depend on the underlying cause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jones, 2019</a>].</li><li>Expert opinion in a review article is that people with asymptomatic, mild hyponatraemia (130–135 mmol/L) may, at least initially, be managed in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jacob, 2019</a>].</li></ul><h6>Repeat serum sodium measurement</h6><ul><li>This recommendation is practical advice based on the US guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Verbalis, 2013</a>] and on what CKS considers to be good clinical practice.<ul><li>A rapidly decreasing serum sodium concentration may be life-threatening. Repeating the serum sodium measurement will help detect at risk people needing admission. The time frame for repeating the serum sodium should be based on clinical judgement.</li></ul></li></ul><h6>Treating an acute illness</h6><ul><li>CKS recommends treating an acute illness as this may resolve the hyponatraemia without further investigation or intervention.</li></ul><h6>Stopping medications that cause hyponatraemia</h6><ul><li>Expert opinion in review articles is that where practical, medications that may cause hyponatraemia should be stopped [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Woodward, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Jacob, 2019</a>]. However, careful follow up may be required to monitor for re-emergence of the condition that was being treated, for example hypertension on withdrawal of a thiazide diuretic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyponatraemia/references/\">Woodward, 2018</a>].</li></ul><!-- end field 0197060d-0c97-4d35-a128-a76900baab8f --><!-- end item 4b97fd5a-7436-4274-9bf5-a76900baab8f -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}